|Bid||18.92 x 800|
|Ask||19.99 x 1000|
|Day's Range||19.16 - 20.40|
|52 Week Range||11.23 - 29.45|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-9.09%|
|Beta (5Y Monthly)||0.00|
|Expense Ratio (net)||0.99%|
If you want to know who really controls Canntab Therapeutics Limited (CNSX:PILL), then you'll have to look at the...
Pharmaceutical ETFs invest in stocks of companies that are involved in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. With Johnson and Johnson continuing ...
Direxion, one of the largest issuers of leveraged exchange traded funds, is planning to change the indexes its leveraged pharmaceuticals and real estate ETFs track. Currently, the Direxion Daily Pharmaceutical ...
NEW YORK , May 31, 2019 /PRNewswire/ -- The Board of Trustees of the Direxion Shares ETF Trust ("Trust") has approved changes to the investment objective, investment strategy and underlying index ...
The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...
Big pharmaceutical companies were on the hot seat at Capitol Hill today with CVS Health, Cigna, Prime Therapeutics, Humana, and UnitedHealthcare's OptumRx testifying before the Senate Finance Committee on the rising cost of prescription drugs. Among the topics discussed included rebates paid by drug makers contributing to the high costs and the drug industry's pursuit of profits--all to shift the blame from the pharmaceutical companies to the drug makers. U.S. President Donald Trump has already lambasted the pharmaceutical industry for the rising costs associated with prescription drugs.
The Daily Pharmaceutical & Medical Bull 3X Shares (PILL) gained 1.35 percent on news that General Electric will sell its biopharmaceutical business to conglomerate company Danaher for $21.4 billion. The sale comes as GE CEO Larry Culp is looking to take the company out of its worst slump in its 127-year history.
According to a report by the Silicon Valley Bank, biopharma deals in 2018 totaled $49 billion and more mergers in 2019 could continue providing growth in the industry, fueling ETFs like Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Direxion Daily S&P Biotech Bull 3X ETF (LABU) . This was evident early in the new year as the biopharma space began 2019 with Bristol-Myers Squibb offering $74 billion to take over Celgene--a deal that could allow Bristol to become a top five pharmaceutical giant. RBC Capital Markets analyst Brian Abrahams said there's "a strong need to diversify around maturing franchises with (patents expiring) and biotech valuations having come down.